Morning Briefing
Summaries of health policy coverage from major news organizations
RTS,S Offers 46 Percent Protection Against Malaria For At Least 15 Months After Vaccination, Study Finds
A Phase II trial published Friday in Lancet Infectious Diseases has shown that RTS,S, the "experimental malaria vaccine from GlaxoSmithKline provides African children with long-lasting protection" against malaria, Reuters reports. "Scientists conducting the mid-stage trial at the Kenya Medical Research Institute said results showing the shot offered 46 percent protection for 15 months meant it had 'promise as a potential public health intervention against childhood malaria in malaria endemic countries'," the news service notes (Kelland, 1/14).
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
